Next generation sequencing and tumor mutation profiling: Are we ready for routine use in the oncology clinic?

BMC Medicine

Volumn 12, Issue 1, 2014, Pages

  Tripathy, Debu ^a   Harnden, Kathleen ^b   Blackwell, Kimberly ^b   Robson, Mark ^c,d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Breast cancer; Next generation sequencing; Oncology

Indexed keywords

IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR;

ACCURACY; ARTICLE; CANCER SUSCEPTIBILITY; CANCER THERAPY; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; HEALTH CARE FACILITY; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG SQUAMOUS CELL CARCINOMA; MOLECULAR DIAGNOSTICS; MOLECULARLY TARGETED THERAPY; NEXT GENERATION SEQUENCING; RNA SEQUENCE; TRIPLE NEGATIVE BREAST CANCER; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION PROFILING; GENETICS; HIGH THROUGHPUT SEQUENCING; MUTATION; NEOPLASM; ONCOLOGY; PERSONALIZED MEDICINE; PROCEDURES; TRENDS;

DNA MUTATIONAL ANALYSIS; GENE EXPRESSION PROFILING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MEDICAL ONCOLOGY; MUTATION; NEOPLASMS; PRECISION MEDICINE;

EID: 84905828163     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-014-0140-3     Document Type: Article

References (34)

1. Chmielecki J, Meyerson M. DNA sequencing of cancer: what have we learned?. Annu Rev Med 2014, 65:63-79. 10.1146/annurev-med-060712-200152, 24274178.
2. Garraway LA, Verweij J, Ballman KV. Precision oncology: an overview. J Clin Oncol 2013, 31:1803-1805. 10.1200/JCO.2013.49.4799, 23589545.
3. Eroglu Z, Tagawa T, Somlo G. Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer. Oncologist 2014, 19:135-150. 10.1634/theoncologist.2013-0283, 24436312.
4. Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F. ALK inhibitors in the treatment of advanced NSCLC. Cancer Treat Rev 2014, 40:300-306. 10.1016/j.ctrv.2013.07.002, 23931927.
5. Jain N, O'Brien S. The frontline treatment of chronic myeloid leukemia in the chronic phase: current clinical decisions and future prospects for treatment. Expert Rev Hematol 2013, 6:575-586. 10.1586/17474086.2013.835697, 24083594.
6. Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, Tan EH, Ho JC, da Chu T, Zaatar A, Osorio Sanchez JA, Vu VV, Au JS, Inoue A, Lee SM, Gebski V, Yang JC. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 2013, 105:595-605. 10.1093/jnci/djt072, 23594426.
7. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012, 367:1694-1703. 10.1056/NEJMoa1210093, 23020132.
8. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483:100-103. 10.1038/nature10868, 22281684.
9. Kurian AW, Hare EE, Mills MA, Kingham KE, McPherson L, Whittemore AS, McGuire V, Ladabaum U, Kobayashi Y, Lincoln SE, Cargill M, Ford JM. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol 2014, 32:2001-2009. 10.1200/JCO.2013.53.6607, 24733792.
10. Andre F, Bachelot T, Commo F, Campone M, Arnedos M, Dieras V, Lacroix-Triki M, Lacroix L, Cohen P, Gentien D, Ade´laide J, Dalenc F, Goncalves A, Levy C, Ferrero JM, Bonneterre J, Lefeuvre C, Jimenez M, Filleron T, Bonnefoi H. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol 2014, 15:267-274. 10.1016/S1470-2045(13)70611-9, 24508104.
11. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Mu¨ller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013, 369:1783-1796. 10.1056/NEJMoa1306494, 24180494.
12. Lee HJ, Schaefer G, Heffron TP, Shao L, Ye X, Sideris S, Malek S, Chan E, Merchant M, La H, Ubhayakar S, Yauch RL, Pirazzoli V, Politi K, Settleman J. Noncovalent wild-type-sparing inhibitors of EGFR T790M. Cancer Discov 2013, 3:168-181. 10.1158/2159-8290.CD-12-0357, 23229345.
13. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Borresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjo¨rd JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinski M, Ja¨ger N, Jones DT, Jones D, Knappskog S, Kool M, et al. Signatures of mutational processes in human cancer. Nature 2013, 500:415-421. 10.1038/nature12477, 23945592.
14. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet 2013, 45:1127-1133. 10.1038/ng.2762, 24071851.
15. My Cancer Genome. www.mycancergenome.org
16. Abrams J, Conley B, Mooney M, Zwiebel J, Chen A, Welch JJ, Takebe N, Malik S, McShane L, Korn E, Williams M, Staudt L, Doroshow J. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. Am Soc Clin Oncol Educ 2014, :71-76.
17. Tinoco G, Warsch S, Gluck S, Avancha K, Montero AJ. Treating breast cancer in the 21st century: emerging biological therapies. J Cancer 2013, 4:117-132. 10.7150/jca.4925, 23386910.
18. Ellis MJ, Buzdar A, Unzeitig GW, Esserman L, Leitch AM, Dershryver K, Allred DC, Suman V, Hunt K, Olson JA. A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer. J Clin Oncol 2010, 28(18, suppl):abstract LBA513.
19. Isakoff SJ, Goss PE, Mayer EL, Traina TA, Carey LA, Krag K, Rugo HS, Liu MC, Stearns V, Come SE, Borger DR, Quadrino CA, Finkelstein D, Garber JE, Ryan PD, Winer EP, Ellisen LW. A multicenter phase II study of cisplatin or carboplatin for metastatic triple negative breast cancer and evaluation of p63/p73 as a biomarker of response. J Clin Oncol 2011, 29(15, suppl):abstract 1025.
20. Baselga J, Majewski I, Nuciforo PG. PI3KCA mutations and correlation with pCR in the NeoALTTO trial (BIG 01-06). Eur Cancer Congress 2013, :abstract 1859.
21. O'Shaughnessy J. Extraordinary responders to lapatinib with trastuzumab in primary-refractory IBC share a common cancer genotype. San Antonio Breast Cancer Symposium 2013, :.
22. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, Lawrence MS, Sivachenko AY, Sougnez C, Zou L, Cortes ML, Fernandez-Lopez JC, Peng S, Ardlie KG, Auclair D, Bautista-Piña V, Duke F, Francis J, Jung J, Maffuz-Aziz A, Onofrio RC, Parkin M, Pho NH, Quintanar-Jurado V, Ramos AH, Rebollar-Vega R, Rodriguez-Cuevas S, Romero-Cordoba SL, Schumacher SE, Stransky N, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012, 486:405-409. 10.1038/nature11154, 22722202.
23. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, Snider J, Ballman K, Weber J, Chen K, Koboldt DC, Kandoth C, Schierding WS, McMichael JF, Miller CA, Lu C, Harris CC, McLellan MD, Wendl MC, DeSchryver K, Allred DC, Esserman L, Unzeitig G, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012, 486:353-360. 22722193.
24. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, Bashashati A, Prentice LM, Khattra J, Burleigh A, Yap D, Bernard V, McPherson A, Shumansky K, Crisan A, Giuliany R, Heravi-Moussavi A, Rosner J, Lai D, Birol I, Varhol R, Tam A, Dhalla N, Zeng T, Ma K, Chan SK, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012, 486:395-399. 22495314.
25. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell GR, Yates LR, Papaemmanuil E, Beare D, Butler A, Cheverton A, Gamble J, Hinton J, Jia M, Jayakumar A, Jones D, Latimer C, Lau KW, McLaren S, McBride DJ, Menzies A, Mudie L, Raine K, Rad R, Chapman MS, Teague J, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012, 486:400-404. 22722201.
26. Blackwell K, Hamilton EP, Marcom PK. Exome sequencing reveals clinically actionable mutations in the pathogenesis and metastasis of triple negative breast cancer. Paper presented at: 36th Annual San Antonio Breast Cancer Symposium; December 10-14 2013, Abstract S4-03., San Antonio, TX.
27. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344:1038-1042. 10.1056/NEJM200104053441402, 11287973.
28. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516. 10.1056/NEJMoa1103782, 21639808.
29. Nelson MR, Wegmann D, Ehm MG, Kessner D, St Jean P, Verzilli C, Shen J, Tang Z, Bacanu SA, Fraser D, Warren L, Aponte J, Zawistowski M, Liu X, Zhang H, Zhang Y, Li J, Li Y, Li L, Woollard P, Topp S, Hall MD, Nangle K, Wang J, Abecasis G, Cardon LR, Zo¨llner S, Whittaker JC, Chissoe SL, Novembre J, Mooser V. An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science 2012, 337:100-104. 10.1126/science.1217876, 22604722.
30. Tennessen JA, Bigham AW, O'Connor TD, Fu W, Kenny EE, Gravel S, McGee S, Do R, Liu X, Jun G, Kang HM, Jordan D, Leal SM, Gabriel S, Rieder MJ, Abecasis G, Altshuler D, Nickerson DA, Boerwinkle E, Sunyaev S, Bustamante CD, Bamshad MJ, Akey JM, Broad GO, Seattle GO. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science 2012, 337:64-69. 10.1126/science.1219240, 22604720.
31. MacArthur DG, Manolio TA, Dimmock DP, Rehm HL, Shendure J, Abecasis GR, Adams DR, Altman RB, Antonarakis SE, Ashley EA, Barrett JC, Biesecker LG, Conrad DF, Cooper GM, Cox NJ, Daly MJ, Gerstein MB, Goldstein DB, Hirschhorn JN, Leal SM, Pennacchio LA, Stamatoyannopoulos JA, Sunyaev SR, Valle D, Voight BF, Winckler W, Gunter C. Guidelines for investigating causality of sequence variants in human disease. Nature 2014, 508:469-476. 10.1038/nature13127, 24759409.
32. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366:883-892. 10.1056/NEJMoa1113205, 22397650.
33. Solit D, Sawyers CL. Drug discovery: How melanomas bypass new therapy. Nature 2010, 468:902-903. 10.1038/468902a, 21164474.
34. Lung Cancer Master Protocol Activation Announcement. Accessed 27 May 2014., http://www.focr.org/sites/default/files/Lung%20Cancer%20Master%20Protocol%20Activation%20Announcement%20Slides.pdf